Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00533455 · ClinicalTrials.gov registry record · Phase 3
Gabapentin for the Treatment of Neuroleptic-Induced Tremor
A Phase 3 study, sponsored by Minneapolis Veterans Affairs Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT00533455 is a Phase 3 study that was terminated before completion, run by Minneapolis Veterans Affairs Medical Center. The registered enrollment target is 40 participants.
The verdict
NCT00533455, a Phase 3 study, was terminated before completion, sponsored by Minneapolis Veterans Affairs Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
We will attempt to establish whether gabapentin as compared with placebo will reduce the severity of tremors caused by the use of antipsychotic medications. Baseline severity of tremor will be measured using both clinical ratings and ratings obtained with an instrument designed to measure tremor, giving more objective evidence of tremor frequency and severity.
Interventions
- DRUG Gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-03 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00533455
The ClinicalTrials.gov registry entry for NCT00533455 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Minneapolis Veterans Affairs Medical Center, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gabapentin is the first listed.
NCT00533455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00533455 about?
NCT00533455 is a clinical study titled "Gabapentin for the Treatment of Neuroleptic-Induced Tremor". We will attempt to establish whether gabapentin as compared with placebo will reduce the severity of tremors caused by the use of antipsychotic medications. Baseline severity of tremor will be measured using both clinical ratings and ratings obtained with an instrument designed to measure tremor, gi...
What is the current status of trial NCT00533455?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2004-03. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00533455?
The interventions under investigation include: Gabapentin (DRUG).
Who is sponsoring clinical trial NCT00533455?
This trial is sponsored by Minneapolis Veterans Affairs Medical Center, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.